Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Gilbert Adjimon Ayelo"'
Autor:
João Fevereiro, Alexandra G. Fraga, Carlos Capela, Ghislain E. Sopoh, Ange Dossou, Gilbert Adjimon Ayelo, Maria João Peixoto, Cristina Cunha, Agostinho Carvalho, Fernando Rodrigues, Jorge Pedrosa
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 223-225 (2021)
Buruli ulcer (BU) is a devastating skin mycobacterial infection characterized by extensive cell death, which was previously suggested to be mediated by Bcl2-like protein 11 (BIM, encoded by the BCL2L11 gene). We here report the association of genetic
Externí odkaz:
https://doaj.org/article/6d2620f8d87b431d8320aa267635c625
Autor:
Esaï Gimatal Anagonou, Roch Christian Johnson, Yves Thierry Barogui, Ghislain Emmanuel Sopoh, Gilbert Adjimon Ayelo, Akpeedje Carolle Wadagni, Jean Gabin Houezo, Didier Codjo Agossadou, Michel Boko
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Buruli ulcer (BU) is a chronic, necrotizing infectious skin disease caused by Mycobacterium ulcerans. In recent years, there has been a decrease in the number of new cases detected. This study aimed to show the evolution of its di
Externí odkaz:
https://doaj.org/article/6ee94ad85d2841b1985c1ab20391edea
Autor:
Gilbert Adjimon Ayelo, Ghislain Emmanuel Sopoh, Jean-Gabin Houezo, René Fiodessihoue, Dissou Affolabi, Ange Dodji Dossou, Yves Thierry Barogui, Akpeedje Anita Carolle Wadagni, Didier Codjo Agossadou, Epco Hasker, Françoise Portaels, Bouke C de Jong, Miriam Eddyani
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 8, p e0006713 (2018)
BACKGROUND:Buruli ulcer (BU) is a chronic necrotizing infectious skin disease caused by Mycobacterium ulcerans. The treatment with BU-specific antibiotics is initiated after clinical suspicion based on the WHO clinical and epidemiological criteria. T
Externí odkaz:
https://doaj.org/article/44f5d6d8d0cd475298edcde3acfd0c04
Autor:
Gilbert Adjimon Ayelo, Esai Anagonou, Anita Carolle Wadagni, Yves Thierry Barogui, Ange Dodji Dossou, Jean Gabin Houezo, Julia Aguiar, Roch Christian Johnson, Raoul Saizonou, Kingsley Asiedu, Ghislain Emmanuel Sopoh
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 3, p e0006358 (2018)
Nigeria is one of the countries endemic for Buruli ulcer (BU) in West Africa but did not have a control programme until recently. As a result, BU patients often access treatment services in neighbouring Benin where dedicated health facilities have be
Externí odkaz:
https://doaj.org/article/fcaa6fa9d9ac4fd0a871328984a09528
Autor:
Carlos Capela, Cristina Cunha, Agostinho Carvalho, João Fevereiro, Ange Dodji Dossou, Fernando Rodrigues, Jorge Pedrosa, Maria João Peixoto, Alexandra G. Fraga, Ghislain Emmanuel Sopoh, Gilbert Adjimon Ayelo
Publikováno v:
Emerging Microbes & Infections. 10:223-225
Buruli ulcer (BU) is a devastating skin mycobacterial infection characterized by extensive cell death, which was previously suggested to be mediated by Bcl2-like protein 11 (BIM, encoded by the BCL...
Autor:
Yves Thierry Barogui, William R. Faber, Luc Brun, Ghislain Emmanuel Sopoh, Dissou Affolabi, Bouke C. de Jong, Annelies Van Rie, Miriam Eddyani, Marleen Boelaert, Jean Jacques Roux, Gilbert Adjimon Ayelo, Françoise Portaels
Publikováno v:
Clinical infectious diseases
Background. The diagnosis of the neglected tropical skin and soft tissue disease Buruli ulcer (BU) is made on clinical and epidemiological grounds, after which treatment with BU-specific antibiotics is initiated empirically. Given the current decline
Autor:
Yves Thierry Barogui, Roch Christian Johnson, Jean Gabin Houezo, Gilbert Adjimon Ayelo, Didier Agossadou, Michel Boko, Akpeedje Anita Carolle Wadagni, Ghislain Emmanuel Sopoh, Esai Anagonou
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-7 (2019)
Background Buruli ulcer (BU) is a chronic, necrotizing infectious skin disease caused by Mycobacterium ulcerans. In recent years, there has been a decrease in the number of new cases detected. This study aimed to show the evolution of its distributio
Autor:
Akpeedje Anita Carolle Wadagni, Yves Thierry Barogui, Miriam Eddyani, René Fiodessihoue, Ange Dodji Dossou, Gilbert Adjimon Ayelo, Epco Hasker, Françoise Portaels, Jean-Gabin Houezo, Ghislain Emmanuel Sopoh, Dissou Affolabi, Didier Agossadou, Bouke C. de Jong
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 12, Iss 8, p e0006713 (2018)
PLoS Neglected Tropical Diseases, Vol 12, Iss 8, p e0006713 (2018)
Background Buruli ulcer (BU) is a chronic necrotizing infectious skin disease caused by Mycobacterium ulcerans. The treatment with BU-specific antibiotics is initiated after clinical suspicion based on the WHO clinical and epidemiological criteria. T
Autor:
Julia Aguiar, Kingsley Asiedu, Yves Thierry Barogui, Jean Gabin Houezo, Anita Carolle Wadagni, Raoul Saizonou, Gilbert Adjimon Ayelo, Ghislain Emmanuel Sopoh, Ange Dodji Dossou, Roch Christian Johnson, Esai Anagonou
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 3, p e0006358 (2018)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Background Nigeria is one of the countries endemic for Buruli ulcer (BU) in West Africa but did not have a control programme until recently. As a result, BU patients often access treatment services in neighbouring Benin where dedicated health facilit
Autor:
Kingsley Asiedu, Jürg Utzinger, Bernard Boua, Agana Nsiire, Wendy Houinei, Damas Obvala, Rita Djupuri, Fasiah Taleo, Camila González-Beiras, Zhang Zaixing, Earnest Njih Tabah, Quique Bassat, Oriol Mitjà, Gilbert Adjimon Ayelo, Yiragnima Kobara, Diby Jean Paul Konan, Michael Marks, Lasse S Vestergaard
Publikováno v:
The Lancet Global Health, Vol 3, Iss 6, Pp e324-e331 (2015)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
BACKGROUND: To achieve yaws eradication, the use of the new WHO strategy of initial mass treatment with azithromycin and surveillance twice a year needs to be extended everywhere the disease occurs. However, the geographic scope of the disease is unk